TYROBP and cancer: The combination of intratumor administration of Ad-P19/DC or Ad-P23/DC can elicit a strong antitumor immune response in vivo, indicating that constitutively activated DAP12 gene therapy could be a useful strategy for directly activating DCs for cancer immunotherapy.